Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced approval from...
FDA has approved two clinical trials studying the effects of PEX010, Filament's botanical psilocybin drug candidate. The post Filament Health Announces...
The FDA gave the nod to the University of Washington and UCLA. The post FDA Greenlights University Research of Filament Psychedelic Drug appeared first...
Source: Clive Maund 08/04/2023 Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you...
Psychedelic science is in its infancy stage, so there is a lot that is still unknown. One of these unknowns is the safety and efficacy of...
Psyence announces a SPAC merger and filing with the SEC for eventual NASDAQ trading. The post Psyence Announces SEC Registration For NASDAQ (by SPAC Merger)...
Awakn Life Sciences has sold its last clinic and shifted its focus entirely to its clinical trials and biotech research. The post Awakn Life Sciences...
Psychedelic medicine is making enormous strides. But many barriers still exist that hinder individuals from accessing psychedelic therapy. The post Barriers...
Psychedelic culture has a long and rich history. It has influenced music, art, and spirituality in profound ways. We take a closer look. The post Psychedelic...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed The post News...